[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100558036":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":35,"locations":45,"responsibleParty":68,"collaborators":29,"id":72,"slug":29,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":29,"eligibilityCriteria":77,"healthyVolunteers":78,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":29,"studyType":85,"phases":86,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":48,"whyStopped":29,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Cairo University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Ketofol Group","EXPERIMENTAL","Five minutes after induction; Ketofol (ketamine to propofol ratio 1:4) will be infused at a rate of 0.6 ml\u002Fkg\u002Fhr. Ketofol will be prepared by adding 40 mg of ketamine to 160 mg of propofol and diluted to 20 ml with normal saline 0.9%.",[13],"Drug: Ketamine",{"label":15,"type":10,"description":16,"interventionNames":17},"Dexmedetomidine","Five minutes after securing the airway, dexmedetomidine infusion will be started at a rate of 0.2 mcg\u002Fkg\u002Fhr.",[18],"Drug: Dexmedetomidine",[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Ketamine","continous infusion during surgery",[9],[26],"propofol",{"type":21,"name":15,"description":23,"armGroupLabels":28,"otherNames":29},[15],null,[31],{"name":32,"affiliation":33,"role":34},"Karim K Fahim","Professor of Anesthesia, Pain management and Surgical ICU Faculty of Medicine, Cairo University.","STUDY_DIRECTOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":29,"email":40},"Muhammad Kh Ibrahim","CONTACT","+201032170260","dr.mki26413@gmail.com",{"name":42,"role":38,"phone":43,"phoneExt":29,"email":44},"Mohamed El Abdelfatah","+201272288695","mohyaseen2@gmail.com",[46,57],{"facility":47,"status":48,"city":49,"state":29,"zip":29,"country":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":29},"Abu Elresh Hospitals ( Cairo university )","RECRUITING","Cairo","Egypt",{"type":52,"coordinates":53},"Point",[54,55],31.24967,30.06263,{"lat":55,"lon":54},{"facility":58,"status":59,"city":49,"state":29,"zip":29,"country":50,"cosmosGeoPoint":60,"geoPoint":62,"contacts":63},"Abu ElResh hospital","NOT_YET_RECRUITING",{"type":52,"coordinates":61},[54,55],{"lat":55,"lon":54},[64],{"name":65,"role":38,"phone":66,"phoneExt":29,"email":67},"Karim M Assem, MD","+201003878369","drknawwar@yahoo.com",{"type":69,"investigatorFullName":70,"investigatorTitle":71,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"PRINCIPAL_INVESTIGATOR","Muhammad Khalaf","principle investigator","100558036",false,"NCT06545890","Ketofol Versus Dexmedetomidine for Prevention of Emergence Delirium in Pediatric Patients Undergoing Squint Surgeries","Ketofol Versus Dexmedetomidine for Prevention of Emergence Delirium in Pediatric Patients Undergoing Squint Surgeries: A Randomized Controlled Study.","Inclusion Criteria:\n\n* • All pediatric patients aged 2 to 6 years.\n\n  * Both sexes.\n  * ASA physical status I and II.\n  * Patients undergoing squint surgery.\n\nExclusion Criteria:\n\n* • Refusal of parents.\n\n  * Patient sensitivity to any of the study medications.\n  * Known neurological disease that can affect the assessment of ED postoperatively.",true,"ALL","2 Years","6 Years",{"count":83,"type":84},46,"ESTIMATED","INTERVENTIONAL",[87,88],"PHASE1","PHASE2","The aim of the study is to compare the effectiveness of ketofol for the prevention of emergence delirium in pediatric patients undergoing squint surgery, in comparison to dexmedetomidine.",[91],"Emergence Delirium",[93,94,95,96],"ketofol","dexmedetomidine","squint surgeries","children","2024-08-16",{"date":99,"type":100},"2024-08-20","ACTUAL",{"date":102,"type":100},"2024-08-10",{"date":104,"type":84},"2024-11-10",{"name":5,"class":6},2]